X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ATG-022 is an antibody-drug conjugate that binds to claudin 18.2, which is being evaluated for the treatment of patients with advanced or metastatic solid tumors.
Lead Product(s): ATG-022
Therapeutic Area: Oncology Product Name: ATG-022
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Details:
ATG-031 is a first-in-class humanized CD24 monoclonal antibody which inhibits the "don't eat me" signal and enhances macrophage-mediated phagocytosis of cancer cells, which is investigated for advanced solid tumors or B-cell non-Hodgkin's lymphoma.
Lead Product(s): ATG-031
Therapeutic Area: Oncology Product Name: ATG-031
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2023
Details:
ATG-031 is a first-in-class humanized CD24 monoclonal antibody which inhibits the "don't eat me" signal and enhances macrophage-mediated phagocytosis of cancer cells, which is investigated for advanced solid tumors or B-cell non-Hodgkin's lymphoma.
Lead Product(s): ATG-031
Therapeutic Area: Oncology Product Name: ATG-031
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
Under the agreement, Hansoh will be exclusively responsible for commercialization of Xpovio (selinexor), world's first approved orally-available, selective inhibitor of the nuclear export protein XPO1, in the mainland of China for relapsed or refractory multiple myeloma.
Lead Product(s): Selinexor,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hansoh Pharma
Deal Size: $101.5 million Upfront Cash: $27.6 million
Deal Type: Collaboration August 10, 2023
Details:
ATG-017 (tizaterkib), an oral, potent, and selective inhibitor of extracellular signal-regulated protein kinase 1 and 2, is being developed in combination with nivolumab in patients with advanced solid tumors.
Lead Product(s): ATG-017,Nivolumab
Therapeutic Area: Oncology Product Name: ATG-017
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export inhibitor approved by the Therapeutic Goods Administration of Australia for patients with relapsed and/or refractory multiple myeloma and in triple class refractory R/R MM.
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
ATG-022 is an antibody-drug-conjugate targeting Claudin 18.2. Claudins are cell adhesion molecules normally expressed within the tight junctions between cells to form a barrier that regulates cell permeability.
Lead Product(s): ATG-022
Therapeutic Area: Oncology Product Name: ATG-022
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
ATG-031 is a first-in-class humanized CD24 monoclonal antibody which inhibits the “don’t eat me” signal and enhances macrophage-mediated phagocytosis of cancer cells. It is being investigated for advanced solid tumors or Bcell non-Hodgkin’s lymphoma.
Lead Product(s): ATG-031
Therapeutic Area: Oncology Product Name: ATG-031
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2023
Details:
Xpovio (selinexor) is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of selective Inhibitor of Nuclear Export (SINE) compounds which down-regulates the levels of multiple oncogenic proteins, for the treatment of cancer.
Lead Product(s): Selinexor
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2023
Details:
ATG-037 is an oral, small molecule CD73 inhibitor. CD73 generates adenosine, which leads to immunosuppression in the tumor microenvironment. ATG-037 has demonstrated promising preclinical efficacy as a monotherapy and in combination with ICIs and chemotherapy agents.
Lead Product(s): ATG-037,Pembrolizumab
Therapeutic Area: Oncology Product Name: ATG-037
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: MSD Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
